Achaogen Inc buy melinda
Start price
25.08.18
/
50%
€4.75
Target price
09.11.18
€9.02
Performance (%)
-49.91%
End price
09.11.18
€2.38
Summary
This prediction ended on 09.11.18 with a price of €2.38. The BUY prediction by melinda for Achaogen Inc performed very badly with a performance of -49.91%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Achaogen Inc | - | - | - | - |
| iShares Core DAX® | -1.347% | 3.576% | 14.229% | 18.356% |
| iShares Nasdaq 100 | 1.169% | 7.020% | 35.388% | 58.850% |
| iShares Nikkei 225® | -0.327% | -0.673% | 8.618% | 6.718% |
| iShares S&P 500 | 0.510% | 4.445% | 28.019% | 49.406% |
Comments by melinda for this prediction
In the thread Achaogen Inc diskutieren
SecteurRecherche biotechnologique et médicale Agenda 07/11 Publication de résultats
Discovers, develops and commercializes novel anti-bacterial to treat multi-drug resistant gram negative infections
Achaogen, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections.
It offers Plazomicin to treat bacterial illness, such as complicated urinary tract infection, blood stream infections, and other infections due to MDR Enterobacteriaceae.
The company was founded by Nathaniel E. David in June 2002 and is headquartered in South San Francisco, CA.
Achaogen, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections.
It offers Plazomicin to treat bacterial illness, such as complicated urinary tract infection, blood stream infections, and other infections due to MDR Enterobacteriaceae.
The company was founded by Nathaniel E. David in June 2002 and is headquartered in South San Francisco, CA.
Nombre d'employés : 230 personnes.
(Vom Mitglied beendet)